Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(1):52-54
DOI: 10.5428/pcar20180113
Alprostadil increases the osteocalcin in postmenopausal women with type 2 diabetes mellitus
1. SUN Fei(Department of Endocrinology,Gongli Hospital of Shanghai Pudong New Area,Shanghai 200135,China sunfei-top@hotmail.com)
2. MA JunHua(Department of Endocrinology,Gongli Hospital of Shanghai Pudong New Area,Shanghai 200135,China )
3. GU MingJun(Department of Endocrinology,Gongli Hospital of Shanghai Pudong New Area,Shanghai 200135,China )
4. WANG JingNan(Department of Endocrinology,Gongli Hospital of Shanghai Pudong New Area,Shanghai 200135,China Jingnan_wang@163.com)
ABSTRACT  Objective: To observe the effect of alprostadil on bone metabolism in postmenopausal women with type 2 diabetes mellitus.Methods: Fifty postmenopausal inpatients with type 2 diabetes mellitus hospitalized from 2015-01-01 to 2016-12-31 were enrolled in this study.They were randomly divided into 2 groups,the control group and the alprostadil group,each consisting of 25 patients.All the patients were treated orally with calcium carbonate (600 mg) and calcitriol (0.25 μg),once a day.Alprostadil (20 μg) was intravenously injected once a day for 14 days in the alprostadil group.The differences in bone metabolism markers were compared between before treatment and 3 months after treatment in the 2 groups.Results: In the control group,there was no significant difference in osteocalcin between before treatment and 3 months after treatment(P>0.05).However,in the alprostadil group,the osteocalcin level 3 months after treatment was significantly higher than that before treatment(P<0.05).Conclusion: Alprostadil used in postmenopausal women with type 2 diabetes mellitus can increase osteocalcin level and promote bone formation.
Welcome to PCAR! You are the number 354 reader of this article!
Please cite this article as:
SUN Fei,MA JunHua,GU MingJun,WANG JingNan,. Alprostadil increases the osteocalcin in postmenopausal women with type 2 diabetes mellitus[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(1): 52-54.
References:
1. SHANG FenLan,XU JingJing,HE RongBo,et al.Research progress in the application of bone turnover markers in diabetes mellitus[J].Chin J Osteoporos,2017,23(4):541-547.In Chinese with English abstract.
2. Shanbhogue V V,Mitchell D M,Rosen C J,et al.Type 2 diabetes and the skeleton:new insights into sweet bones[J].Lancet Diabetes Endocrinol,2016,4(2):159-173.
3. Melton L J 3rd,Riggs B L,Leibson C L,et al.A bone structural basis for fracture risk in diabetes[J].J Clin Endocrinol Metab,2008,93(12):4804-4809.
4. Burghardt A J,Issever A S,Schwartz A V,et al.High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2010,95(11):5045-5055.
5. ZHOU XueYing,XIA WeiBo.Biochemical markers of bone turnover[J].Basic Clin Med,2007,27(10):1093-1100.In Chinese with English abstract.
6. PAN HuaiZhong,Sima M,Miller S C,et al.Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats[J].Biomaterials,2013,34(27):6528-6538.
7. Starup-Linde J,Eriksen S A,Lykkeboe S,et al.Biochemical markers of bone turnover in diabetes patients-a meta-analysis, and a methodological study on the effects of glucose on bone markers[J].Osteoporos Int,2014,25(6):1697-1708.
8. Miller S C,Marks S C Jr.Effects of prostaglandins on the skeleton[J].Clin Plast Surg,1994,21(3):393-400.
9. Kainuma S,Otsuka T,Kuroyanagi G,et al.Possible involvement of AMP-activated protein kinase in PGE1-induced synthesis of osteoprotegerin in osteoblasts[J].Exp Ther Med, 2016,11(5):2042-2048.
10. da Silva Sasso G R,Florencio-Silva R,Simes R S,et al.Elevated serum osteoprotegerin levels in women: friend or foe?[J].Rev Assoc Med Bras,2015,61(6):524-529.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口